BioSpace News Archive

Model N, Inc., the leader in revenue optimization and compliance, announced that Model N management will present at the following investor conferences: The Jefferies 2023 Software Conference on Thursday, June 1, 2023 at 9:00 a.m. PT.

HeartBeam, Inc. (NASDAQ: BEAT) today announced it has received a notice of allowance from The United States Patent and Trademark Office for a key patent relating to the initial AI capability in the form of an expert system for its HeartBeam AIMIGoTM System.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference.

Today, the U.S. Food and Drug Administration approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

DAXOR CORPORATION, the global leader in blood volume measurement technology, announced the closing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 per share.

Inventiva and Sino Biopharm, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., announce that CTTQ received Investigational New Drug approval from the Chinese National Medical Products Administration on May 22nd 2023, and can now initiate the clinical development of Inventiva’s lead compound lanifibranor in mainland China.

Landos Biopharma, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time today, May 25, 2023.

Standard BioTools Inc. announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:00 a.m. ET.

Genelux Corporation, a late clinical-stage immuno-oncology company, announced the publication of positive topline results from its Phase 2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or -refractory ovarian cancer in JAMA Oncology.

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced its first quarter 2023 financial results.